Dapagliflozin (Forxiga), a new once-daily tablet to improve blood glucose control for adults with type 2 diabetes, has been granted Marketing Authorisation by the European Commission. This treatment is for use in combination with other glucose lowering treatments, including insulin when these, together with diet and exercise, do not provide adequate blood glucose control in patients. It can also be used as a monotherapy when diet and exercise alone do not work in patients for whom the blood glucose lowering product metformin cannot be tolerated. The introduction of dapagliflozin will provide physicians with a treatment option that is the first of a new treatment class for type 2 diabetes. Evidence has shown that dapagliflozin effectively lowers and maintains reduced blood glucose levels (HbA1c) in adults with type 2 diabetes for two years and is generally well tolerated. It also has the additional secondary benefit of weight loss sustained for two years. Dapaglifozin also offers a novel way of working in people with type 2 diabetes, expelling excess glucose out of the body via the urine along with the associated calories. This is independent of insulin action and it is developed from phlorizin, a naturally occurring sugar compound found in the bark of apple trees. Professor Clifford Bailey, Professor of Clinical Science at Aston University, commented: “Controlling blood glucose is crucial to managing type 2 diabetes and the risk of developing complications. Weight management is also important. Dapaglifozin works in a different way to existing treatments. It removes excess glucose from the body along with the associated calories. This process occurs independently of insulin action. So dapaglifozin can be used in conjunction with most commonly used diabetes medications to lower blood glucose, and has the added benefit of weight loss.” Type 2 diabetes affects an estimated 2.6 million people in the UK, nearly half of whom are uncontrolled on their current treatment regimens. Up to now, the development of treatments for type 2 diabetes has focused primarily on mechanisms that rely on the body’s own insulin, a hormone that helps to keep blood glucose at normal levels.